Catalent (NYSE:CTLT) Now Covered by StockNews.com

StockNews.com assumed coverage on shares of Catalent (NYSE:CTLT) in a research note issued to investors on Saturday morning. The brokerage issued a hold rating on the stock.

Other research analysts also recently issued research reports about the stock. Baird R W downgraded shares of Catalent from a “strong-buy” rating to a “hold” rating in a report on Tuesday, September 24th. Robert W. Baird reaffirmed a “neutral” rating and issued a $63.50 price objective on shares of Catalent in a research note on Tuesday, September 24th. Eight analysts have rated the stock with a hold rating, Based on data from MarketBeat, Catalent currently has an average rating of “Hold” and an average target price of $63.40.

Catalent Stock Performance

NYSE CTLT opened at $63.48 on Friday. The company has a debt-to-equity ratio of 1.38, a current ratio of 2.51 and a quick ratio of 1.96. Catalent has a 1-year low of $41.15 and a 1-year high of $63.50. The business has a 50 day simple moving average of $61.27 and a two-hundred day simple moving average of $59.84. The stock has a market capitalization of $11.52 billion, a PE ratio of -28.09, a P/E/G ratio of 2.70 and a beta of 1.15.

Catalent (NYSE:CTLT) last posted its earnings results on Tuesday, November 5th. The company reported ($0.13) earnings per share for the quarter, missing analysts’ consensus estimates of $0.05 by ($0.18). The business had revenue of $1.02 billion during the quarter, compared to analysts’ expectations of $1.06 billion. Catalent had a negative net margin of 9.28% and a negative return on equity of 0.66%. The company’s revenue for the quarter was up 4.2% compared to the same quarter last year. During the same period last year, the business posted ($0.10) earnings per share. On average, research analysts predict that Catalent will post 0.78 EPS for the current fiscal year.

Insider Activity

In other news, Director Michelle R. Ryan sold 2,800 shares of the business’s stock in a transaction on Monday, November 11th. The shares were sold at an average price of $59.70, for a total transaction of $167,160.00. Following the completion of the sale, the director now directly owns 10,835 shares of the company’s stock, valued at approximately $646,849.50. The trade was a 20.54 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Insiders own 0.31% of the company’s stock.

Institutional Investors Weigh In On Catalent

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Athos Capital Ltd purchased a new position in shares of Catalent during the third quarter worth approximately $6,009,000. Oddo BHF Asset Management Sas purchased a new position in Catalent during the 3rd quarter worth $8,480,000. State Street Corp increased its holdings in Catalent by 1.5% during the 3rd quarter. State Street Corp now owns 7,451,135 shares of the company’s stock worth $451,315,000 after purchasing an additional 113,095 shares during the period. Dynamic Technology Lab Private Ltd purchased a new stake in shares of Catalent in the 3rd quarter worth $1,131,000. Finally, Sumitomo Mitsui Trust Group Inc. lifted its holdings in shares of Catalent by 3.7% in the 3rd quarter. Sumitomo Mitsui Trust Group Inc. now owns 405,318 shares of the company’s stock worth $24,550,000 after buying an additional 14,373 shares during the period.

Catalent Company Profile

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules.